We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
Read MoreHide Full Article
A strong stock as of late has been Progyny (PGNY - Free Report) . Shares have been marching higher, with the stock up 2.4% over the past month. The stock hit a new 52-week high of $27.76 in the previous session. Progyny has gained 56.3% since the start of the year compared to the 7.6% move for the Zacks Medical sector and the 6.9% return for the Zacks Medical Services industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 6, 2025, Progyny reported EPS of $0.45 versus consensus estimate of $0.39 while it beat the consensus revenue estimate by 4.19%.
For the current fiscal year, Progyny is expected to post earnings of $1.8 per share on $1.27 in revenues. This represents a 9.76% change in EPS on a 9.16% change in revenues. For the next fiscal year, the company is expected to earn $1.93 per share on $1.39 in revenues. This represents a year-over-year change of 7.22% and 9.24%, respectively.
Valuation Metrics
While Progyny has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Progyny has a Value Score of B. The stock's Growth and Momentum Scores are A and D, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 15X current fiscal year EPS estimates, which is not in-line with the peer industry average of 15.6X. On a trailing cash flow basis, the stock currently trades at 78.1X versus its peer group's average of 11X. Additionally, the stock has a PEG ratio of 0.9. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Progyny currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny passes the test. Thus, it seems as though Progyny shares could still be poised for more gains ahead.
How Does PGNY Stack Up to the Competition?
Shares of PGNY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is CareDx, Inc. (CDNA - Free Report) . CDNA has a Zacks Rank of #2 (Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of C.
Earnings were strong last quarter. CareDx, Inc. beat our consensus estimate by 115.38%, and for the current fiscal year, CDNA is expected to post earnings of $0.77 per share on revenue of $374.08 million.
Shares of CareDx, Inc. have gained 11.5% over the past month, and currently trade at a forward P/E of 29.01X and a P/CF of 14.72X.
The Medical Services industry may rank in the bottom 66% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for PGNY and CDNA, even beyond their own solid fundamental situation.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
A strong stock as of late has been Progyny (PGNY - Free Report) . Shares have been marching higher, with the stock up 2.4% over the past month. The stock hit a new 52-week high of $27.76 in the previous session. Progyny has gained 56.3% since the start of the year compared to the 7.6% move for the Zacks Medical sector and the 6.9% return for the Zacks Medical Services industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 6, 2025, Progyny reported EPS of $0.45 versus consensus estimate of $0.39 while it beat the consensus revenue estimate by 4.19%.
For the current fiscal year, Progyny is expected to post earnings of $1.8 per share on $1.27 in revenues. This represents a 9.76% change in EPS on a 9.16% change in revenues. For the next fiscal year, the company is expected to earn $1.93 per share on $1.39 in revenues. This represents a year-over-year change of 7.22% and 9.24%, respectively.
Valuation Metrics
While Progyny has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Progyny has a Value Score of B. The stock's Growth and Momentum Scores are A and D, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 15X current fiscal year EPS estimates, which is not in-line with the peer industry average of 15.6X. On a trailing cash flow basis, the stock currently trades at 78.1X versus its peer group's average of 11X. Additionally, the stock has a PEG ratio of 0.9. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Progyny currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny passes the test. Thus, it seems as though Progyny shares could still be poised for more gains ahead.
How Does PGNY Stack Up to the Competition?
Shares of PGNY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is CareDx, Inc. (CDNA - Free Report) . CDNA has a Zacks Rank of #2 (Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of C.
Earnings were strong last quarter. CareDx, Inc. beat our consensus estimate by 115.38%, and for the current fiscal year, CDNA is expected to post earnings of $0.77 per share on revenue of $374.08 million.
Shares of CareDx, Inc. have gained 11.5% over the past month, and currently trade at a forward P/E of 29.01X and a P/CF of 14.72X.
The Medical Services industry may rank in the bottom 66% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for PGNY and CDNA, even beyond their own solid fundamental situation.